Social return on investment-informed analysis of immunoglobulin therapy for inborn errors of immunity in France

Aim: Social return on investment (SROI) is a framework that quantifies both economic and societal value relative to investment. Inborn errors of immunity (IEI), also referred to as primary immunodeficiencies, are chronic conditions that impose substantial clinical and societal burdens, which are underrepresented in traditional economic evaluations. This study aimed to estimate the SROI of immunoglobulin (IG) therapy compared with non-IG therapy (alternative treatments or no treatment) for patients with IEI in France. Materials & methods: A closed-cohort model was developed to compare IG therapy with non-IG therapy over a 3-year horizon. The model included direct healthcare costs (drug acquisition, administration and healthcare resource use) and indirect societal costs (productivity loss, informal care, mental health support, transportation, sick leave and lost tax revenue). Four perspectives were evaluated, ranging from most to least inclusion of societal elements: Societal, Collective, Complete Payer and National Health Insurance. Inputs were derived from French real-world data, published literature and expert validation. Results: Over 3 years, IG therapy generated positive returns across all perspectives, with SROI ratios ranging from €1.10 to €1.30, indicating that each euro invested returned more than €1 in combined value. Total savings ranged from €488.0 million to €581.9 million, driven by reduced healthcare and societal costs in the IG therapy scenario. The societal perspective yielded the highest SROI and greatest savings, reflecting broad inclusion of societal aspects. Conclusion: IG therapy provides substantial value in IEI management, where both economic and societal savings outweigh the cost of IG therapy. These findings support the role of IG therapy as a high-value intervention and underscore the importance of incorporating SROI into decision-making to capture benefits beyond direct medical costs.

Authors

Institutions

Publication Details

Journal
Journal of Comparative Effectiveness Research
Published
2026-11-19
DOI
https://doi.org/10.57264/cer-2026-0084
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Social return on investment-informed analysis of immunoglobulin therapy for inborn errors of immunity in France

Rebecca K. McTavish, Dilan D. Patel, Stacey Priest, Batyrkhan Kuatov et al.
Journal of Comparative Effectiveness Research
Health Systems, Economic Evaluations, Quality of Life
article

Social return on investment-informed analysis of immunoglobulin therapy for inborn errors of immunity in France

Rebecca K. McTavish, Dilan D. Patel, Stacey Priest, Batyrkhan Kuatov, Laurence Undreiner, Melike INKAYA. TASKIN
article en

Abstract

Aim: Social return on investment (SROI) is a framework that quantifies both economic and societal value relative to investment. Inborn errors of immunity (IEI), also referred to as primary immunodeficiencies, are chronic conditions that impose substantial clinical and societal burdens, which are underrepresented in traditional economic evaluations. This study aimed to estimate the SROI of immunoglobulin (IG) therapy compared with non-IG therapy (alternative treatments or no treatment) for patients with IEI in France. Materials & methods: A closed-cohort model was developed to compare IG therapy with non-IG therapy over a 3-year horizon. The model included direct healthcare costs (drug acquisition, administration and healthcare resource use) and indirect societal costs (productivity loss, informal care, mental health support, transportation, sick leave and lost tax revenue). Four perspectives were evaluated, ranging from most to least inclusion of societal elements: Societal, Collective, Complete Payer and National Health Insurance. Inputs were derived from French real-world data, published literature and expert validation. Results: Over 3 years, IG therapy generated positive returns across all perspectives, with SROI ratios ranging from €1.10 to €1.30, indicating that each euro invested returned more than €1 in combined value. Total savings ranged from €488.0 million to €581.9 million, driven by reduced healthcare and societal costs in the IG therapy scenario. The societal perspective yielded the highest SROI and greatest savings, reflecting broad inclusion of societal aspects. Conclusion: IG therapy provides substantial value in IEI management, where both economic and societal savings outweigh the cost of IG therapy. These findings support the role of IG therapy as a high-value intervention and underscore the importance of incorporating SROI into decision-making to capture benefits beyond direct medical costs.

Journal of Comparative Effectiveness Research
EVERSANA (Canada) (CA), CSL (Switzerland) (CH)
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon